NCT06085677|Unknown
The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
GEM
Loading search results
GEM
Sponsor study identifier
observational
600
0 countries
N/A
Study Start
November 4, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
September 2, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The goal of the study is to understand whether blood levels of hormones produced or metabolized in the stomach reflect the health of the stomach lining. Specifically the study will determine whether the concentration of ghrelin, gastrin, pepsinogens and vitamin B12 reflect the condition of the stomach lining. Hormone concentrations for people with normal/mild gastritis will be compared to people with long-term inflammation of the stomach (chronic atrophic gastritis), and people with pre-cancerous cellular changes (intestinal metaplasia).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 10, 2023
Actual (reported)October 17, 2023
Actual (reported)November 4, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 2, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 2, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Serologic concentrations of ghrelin, gastrin, pepsinogens and vitamin B12
Serologic concentrations for patients with atrophic gastritis and intestinal metaplasia will be compared to normal/mild gastritis controls.
Measurements will be made on conclusion of the study, one year after enrollment begins
Patients enrolled with normal stomach epithelium or mild gastritis
Patients enrolled with chronic atrophic gastritis
Patients enrolled with intestinal metaplasia
Patients scheduled for endoscopy within the endoscopy service at participating sites will be invited to participate in the study and provide a blood sample.
Venous blood draw
Gwen Murphy, PhD MPH
Imperial College Dublin
First Submitted
October 10, 2023
First Posted
October 17, 2023
Study Start
November 4, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
September 2, 2024
The Role of Artificial Intelligence in Endoscopic Diagnosis of Esophagogastric Junctional Adenocarcinoma：A Single Center, Case-control, Diagnostic Study
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 17, 2023
Record last verified: 2023-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: